非戈替尼治疗溃疡性结肠炎患者快速且持续的症状缓解:2b/3期SELECTION试验数据
该事后分析基于双盲、随机、安慰剂对照的58周SELECTION试验,评估非戈替尼200 mg对中重度活动性溃疡性结肠炎患者症状缓解的快速性与持续性。结果显示非戈替尼200 mg较安慰剂在7天内改善直肠出血和排便频率,第2周及第58周达到部分Mayo临床评分缓解的患者比例更高,早期症状改善与第10周和第58周Mayo临床评分应答相关,且第10周和第58周达到部分Mayo临床评分缓解的患者炎症性肠病问卷评分改善更大。
要点
- 非戈替尼200 mg较安慰剂在7天内改善直肠出血和排便频率(P<0.05)。
- 第2周部分Mayo临床评分缓解率:生物制剂初治患者15.1% vs 8.0%(P=0.0410),生物制剂经治患者10.3% vs 4.2%(P=0.0274)。
- 第10周和第58周达到部分Mayo临床评分缓解的患者炎症性肠病问卷评分改善更大。
核心结论
- 非戈替尼200 mg每日一次可快速且持续改善溃疡性结肠炎症状和健康相关生活质量。
研究设计与样本
- SELECTION试验(NCT02914522)为双盲、随机、安慰剂对照的58周2b/3期试验,本分析为其事后分析。
主要发现
- 非戈替尼200 mg较安慰剂在7天内改善直肠出血和排便频率(P<0.05)。
- 第2周部分Mayo临床评分缓解率:生物制剂初治患者非戈替尼200 mg组15.1% vs 安慰剂组8.0%(P=0.0410);生物制剂经治患者非戈替尼200 mg组10.3% vs 安慰剂组4.2%(P=0.0274)。
- 第58周观察到相似的治疗效应(P<0.0001)。
- 第7天直肠出血和排便频率子评分与第10周和第58周Mayo临床评分应答相关。
- 第10周和第58周达到部分Mayo临床评分缓解的患者较未达到者炎症性肠病问卷评分改善更大。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with ulcerative colitis (UC) regard rapid onset of action among the most important aspects of their treatment. We used the partial Mayo Clinic Score (pMCS) and component patient-reported subscores to assess the rapidity and sustainability of response to filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor, in adults with moderately to severely active UC in the phase 2b/3 SELECTION trial. The association between early symptomatic improvements and health-related quality of life (HRQoL) outcomes was also assessed. METHODS: In these post hoc analyses of the double-blinded, randomized, placebo-controlled 58-week SELECTION trial (NCT02914522), rectal bleeding and stool frequency diary data on days 1-15 and pMCS remission and response at multiple time points including weeks 10 and 58 were evaluated. HRQoL was assessed using the Inflammatory Bowel Disease Questionnaire at weeks 10 and 58. RESULTS: Filgotinib 200 mg relative to placebo improved rectal bleeding and stool frequency within 7 days ( P < 0.05). By week 2, greater proportions of filgotinib 200 mg-treated patients than placebo-treated patients achieved pMCS remission (biologic-naive, 15.1% vs 8.0%, P = 0.0410; biologic-experienced, 10.3% vs 4.2%, P = 0.0274). A similar treatment effect was observed at week 58 ( P < 0.0001). Day 7 rectal bleeding and stool frequency subscores were associated with the Mayo Clinic Score response at weeks 10 and 58. Patients in pMCS remission at weeks 10 and 58 had greater improvements in the Inflammatory Bowel Disease Questionnaire score than those not in pMCS remission. DISCUSSION: Filgotinib 200 mg daily resulted in rapid and sustained improvements in both UC symptoms and HRQoL.
引用
- Danese S, Ferrante M, Feagan BG, et al. Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial. Am J Gastroenterol. 2022. PMID: 36113491. doi:10.14309/ajg.0000000000001979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。